<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04210193</url>
  </required_header>
  <id_info>
    <org_study_id>ILIT Borås EPN 2014/251</org_study_id>
    <nct_id>NCT04210193</nct_id>
  </id_info>
  <brief_title>Is Intralymphatic Allergen Immunotherapy Effective and Safe?</brief_title>
  <official_title>Is Intralymphatic Allergen Immunotherapy Effective and Safe: a Human Randomized Clinical Trial- Substudy Borås With a Randomized Preseasonal Booster</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lars Olaf Cardell</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      15 patients with moderate to severe allergic rhinitis against grass were recruited and
      enrolled in the study. They received three open label intralympatic grass allergen injections
      with the dose 1000 SQ-U each and with one month interval. The next year the patients were
      randomized double blind to an active or placebo booster injection of 1000 SQ-U before the
      pollen season. Grass specific IgG4 levels were measured before and at various time ponts
      after treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to evaluate whether intralymphatic administration of AIT is a
      safe and effective treatment for patients with pollen-induced allergic rhinitis. The long
      term goal is to provide a base for a more efficient administration of ASIT, which will reduce
      both the dose necessary and the number of clinic visits associated with the conventional
      subcutaneous ASIT.

      The aim of the present substudy is to evaluate if a randomized preseasonal ILIT booster,
      after three open label ILIT injections, can increase the allergen specific IgG4 antibodies,
      and if the IgG4 increase can be correlated to clinical effect characterized with seasonal
      questionnaires.

      The first part of the study is completed and published (PMID: 23374268)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 25, 2014</start_date>
  <completion_date type="Actual">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the serum-level of timothy specific IgG4 after 1 month</measure>
    <time_frame>Change between baseline and 1 month after treatment.</time_frame>
    <description>Blood samples with measurement of allergen specific blocking IgG4 antibodies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the serum-level of timothy specific IgG4 after 9 months</measure>
    <time_frame>Change between baseline and 9 months after treatment.</time_frame>
    <description>Blood samples with measurement of allergen specific blocking IgG4 antibodies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the serum-level of timothy specific IgG4 2 months after booster</measure>
    <time_frame>Change between baseline and 2 months after the booster treatment (14 months after the basic treatment).</time_frame>
    <description>Blood samples with measurement of allergen specific blocking IgG4 antibodies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the serum-level of timothy specific IgG4 10 months after booster</measure>
    <time_frame>Change between baseline and 10 months after the booster treatment (22 months after the basic treatment).</time_frame>
    <description>Blood samples with measurement of allergen specific blocking IgG4 antibodies</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Allergic Rhinitis Due to Grass Pollen</condition>
  <arm_group>
    <arm_group_label>Active booster</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After three basic open label grass allergen ILIT injections the patient is randomized to an active ILIT booster 1 year after the first treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo booster</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After three basic open label grass allergen ILIT injections the patient is randomized to a placebo ILIT booster 1 year after the first treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALK Alutard 5-grasses</intervention_name>
    <description>0.1 mL of 10 000 SQ-U/mL (1000 SQ-U) as an intralymphatic injection</description>
    <arm_group_label>Active booster</arm_group_label>
    <other_name>Grass allergen with aluminum adjuvant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALK Diluent</intervention_name>
    <description>0.1 mL of ALK Diluent as an intralymphatic injection</description>
    <arm_group_label>Placebo booster</arm_group_label>
    <other_name>Human albumin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-50,

          -  Seasonal allergic symptoms for birch and/or grass verified by skin prick test,

          -  Accepted informed consent

        Exclusion Criteria:

          -  Pregnancy or nursing

          -  Autoimmune or collagen disease (known)

          -  Cardiovascular disease

          -  Perennial pulmonary disease

          -  Hepatic disease

          -  Renal disease

          -  Cancer

          -  Any medication with a possible side-effect of interfering with the immune response

          -  Previous immuno- or chemotherapy

          -  Chronic diseases

          -  Other upper airway disease (non-allergic sinusitis, nasal polyps, chronic obstructive
             and restrictive lung disease)

          -  Disease or conditions rendering the treatment of anaphylactic reactions difficult
             (symptomatic coronary heart diseases, severe arterial hypertension and treatment with
             β-blockers)

          -  Major metabolic disease

          -  Known or suspected allergy to the study product

          -  Alcohol or drug abuse

          -  Mental incapability of coping with the study

          -  Withdrawal of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Olaf Cardell, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergy Unit, Södra Älvsborgs Hospital</name>
      <address>
        <city>Borås</city>
        <zip>501 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Hylander T, Larsson O, Petersson-Westin U, Eriksson M, Kumlien Georén S, Winqvist O, Cardell LO. Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial. Respir Res. 2016 Jan 27;17:10. doi: 10.1186/s12931-016-0324-9.</citation>
    <PMID>26817454</PMID>
  </reference>
  <reference>
    <citation>Konradsen JR, Grundström J, Hellkvist L, Tran TAT, Andersson N, Gafvelin G, Kiewiet MBG, Hamsten C, Tang J, Parkin RV, Shamji MH, Hedlin G, Cardell LO, van Hage M. Intralymphatic immunotherapy in pollen-allergic young adults with rhinoconjunctivitis and mild asthma: A randomized trial. J Allergy Clin Immunol. 2020 Mar;145(3):1005-1007.e7. doi: 10.1016/j.jaci.2019.11.017. Epub 2019 Nov 24.</citation>
    <PMID>31775016</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Lars Olaf Cardell</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

